BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:INCA033989 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of INCA033989\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05936359-10795@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:INCA033989: Phase 1 readout est. (NCT05936359)
DESCRIPTION:INCA033989\, phase 1.\nStudy: A Study to Evaluate INCA033989 Ad
 ministered as a Monotherapy or in Combination With Ruxolitinib in Particip
 ants With Myeloproliferative Neoplasms\nEstimated primary completion: 29 F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inca033
 989#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05936359
URL:https://assetmemo.bio/drug/inca033989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06034002-10795@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20281029
DTEND;VALUE=DATE:20281030
SUMMARY:INCA033989: Phase 1 readout est. (NCT06034002)
DESCRIPTION:INCA033989\, phase 1.\nStudy: A Study to Evaluate INCA033989 Ad
 ministered as a Monotherapy or in Combination With Ruxolitinib in Particip
 ants With Myeloproliferative Neoplasms\nEstimated primary completion: 29 O
 ctober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inca0339
 89#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6034002
URL:https://assetmemo.bio/drug/inca033989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623200-10795@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:INCA033989: Phase 3 readout est. (NCT07623200)
DESCRIPTION:INCA033989\, phase 3\, Essential Thrombocythemia.\nStudy: A Pha
 se 3 Study of INCA033989 Versus Best Available Therapy in Participants Wit
 h Essential Thrombocythemia\nEstimated primary completion: 15 June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/inca033989#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07623200
URL:https://assetmemo.bio/drug/inca033989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
